



NEWS RELEASE

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

3/26/2024

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- **Evolus, Inc.** (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the following investor conference in April:

Event: The 23rd Annual Needham Virtual Healthcare Conference

Date: Tuesday, April 9th, 2024

Time: 9:30 – 10:10 AM ET

The fireside chat can be accessed on the Investor Relations page of the Evolus website [here](#). A replay of the webcast will be available for 90 days following the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau[®] (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure[™] technology. Evolus is expanding its product portfolio having entered into a definitive agreement to be the exclusive U.S. distributor of Evolysse[™], and the exclusive distributor in Europe of Estyme[®], a line of unique dermal fillers currently in late-stage development. Visit us at

www.evolus.com, and follow us on **LinkedIn, X, Instagram** or **Facebook**.

Jeuveau[®] and Nuceiva[®] are registered trademarks of Evolus, Inc.

Evolysse[™] is a trademark of Evolus, Inc.

Hi-Pure[™] is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: **ir@evolus.com**

Media:

Email: **media@evolus.com**

Source: Evolus